프리마켓
로그인 회원가입
TVGN
TVGN
Tevogen Bio Holdings Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$5.57
+1.08 ▲ +24.05%
🌙 7월 28일 7:14 AM ET (한국 7/28 20:14)
$5.55
-0.02 ▼ -0.36%

테보젠 바이오 홀딩스(TVGN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$24M
스몰캡
P/E
-
배당수익률
없음
52주 위치
3%
저점 +53% · 고점 -92%
애널리스트
보유
F
Fundamental health
vs. 방어주 초소형주· based on 1 axes
수익성
산출 불가 (적자)
성장
데이터 부족
밸류에이션
데이터 부족
재무 안정
Top 92%
Index -P/E -EPS (ttm) -5.84Insider Own 73.82%Shs Outstand 4.2MPerf Week 43.19%
Market Cap 0.02BForward P/E -EPS next Y -Insider Trans -0.03%Shs Float 1.1MPerf Month -41.61%
Enterprise Value 0.04BPEG -EPS next Q -Inst Own 3.24%Short Float 5.9%Perf Quarter -26.23%
Income -0.02BP/S -EPS this Y -Inst Trans 46.03%Short Ratio 2.43Perf Half Y -68.16%
Sales 0.00BP/B -EPS next 5Y -ROA -474.85%Short Interest 0.06MPerf YTD -66.35%
Book/sh -4.47P/C 34.05EPS past 3/5Y - -305.12%ROE -52W High -92.04% ($70.00)Perf Year -89.49%
Cash/sh 0.16P/FCF -Sales past 3/5Y -ROIC -52W Low 53.17% ($3.64)Perf 3Y -98.96%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 38.95%Gross Margin -Volatility(W/M) 11.58% 12.43%Perf 5Y -
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.75Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.29EPS Q/Q 50.45%Profit Margin -RSI (14) 47.45Recom 3
Dividend Gr. 3/5Y -Current Ratio 0.29Sales Q/Q -SMA20 10.52% ($5.04)Beta 0.27Target Price $100
Payout -Debt/Eq -Earnings 2026/02/25SMA50 -27.73% ($7.71)Rel Volume 0.73Prev Close $4.49
Employees 18LT Debt/Eq -EPS/Sales Surpr. 50.66% -SMA200 -60.4% ($14.07)Avg Volume(3M) 0.03MPrice $5.57
IPO 2022/1/5Option/Short No/YesTrades 213Volume 19,576Change 24.05%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-5M (YoY +47%)

📊 Tevogen Bio Holdings Inc (TVGN) Investment Analysis

What kind of company is Tevogen Bio Holdings Inc?

테보젠 바이오 홀딩스(TVGN) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧫 Tevogen Bio (Tevogen Biosciences) is a clinical-stage biotech developing off-the-shelf precision T-cell therapies using its 'ExacTcell' platform to target viruses, cancer, and autoimmune diseases. Its lead candidate, TVGN 489, is a SARS-CoV-2-specific CD8+ T-cell therapy.

Learn more about Tevogen Bio Holdings Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5211
Employees18people
IPO2022/01/05
Current Price$5.57 ≈ 7,631원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 2월 25일 (수) · 장 마감 후 EPS +50.7%

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
ROA
Annual earnings relative to total company assets
-474.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.29
✓ 위험
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.29
✓ 위험
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$100.00
현재가 대비 +1695.3%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 1 of the last 1 quarters
1
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+50.7%
평균 서프라이즈
2026.02.25
상회
+50.7%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-305.1%
매우 부진
My positionBottom 5%
Low range Average High range
방어주 초소형주 Median 16.4% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Underperformed the market by 105%p over the past year
TVGN -89.5% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-105.5%p
Significantly behind the market
vs Health Care (XLV)
-109.2%p
Significantly behind the sector average
Rank among peers
1-year return Bottom 12% Based on 315 peers
Current position within 52-week range
Low (-53.2%p) High (-92.0%p)
Current price is 53.2% above the 52-week low and 92.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-66.7%
Annualized volatility
574.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $5.57 above the midline ($5.04). Normal upward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD -0.928 · Signal -1.061 · Hist 0.134. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 47.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 91.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Valuation data is insufficient

Key metrics such as PER and PBR are unavailable, so valuation is omitted.

Who owns it?

Ownership flow is positive
Insider modest net selling -0.0% · Institutional net buying +46.0% · Short interest moderate 5.9% · Short interest fell -0.7%p over the last 85 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-0.0%
Insiders little change
🏦 Institutions (funds & investors)
+46.0%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 3.2%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 73.8%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 22.9%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
5.9%
Moderate
Healthcare 초소형주 Median 3.9%
Past 85 days 📉 -0.7%p decrease
Short interest days to cover
2.4 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 4.2M주
Float (tradable shares) 1.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 85 days.

ETFs holding TVGN

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
TVGN TVGN This Stock
$23.5M- - - - +24.1%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 테보젠 바이오 홀딩스(TVGN)?

테보젠 바이오 홀딩스(TVGN) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of TVGN?

The market cap of TVGN is approximately $24M, ranking 5,211 within its sector.

What is the 52-week high and low for TVGN?

TVGN has recorded a 52-week high of $70.00 and a low of $3.64.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.